168 related articles for article (PubMed ID: 20123473)
1. Psychosocial aspects of PKU: hidden disabilities--a review.
Gentile JK; Ten Hoedt AE; Bosch AM
Mol Genet Metab; 2010; 99 Suppl 1():S64-7. PubMed ID: 20123473
[TBL] [Abstract][Full Text] [Related]
2. Psychiatric symptoms and disorders in phenylketonuria.
Brumm VL; Bilder D; Waisbren SE
Mol Genet Metab; 2010; 99 Suppl 1():S59-63. PubMed ID: 20123472
[TBL] [Abstract][Full Text] [Related]
3. Mental health and social functioning in early treated Phenylketonuria: the PKU-COBESO study.
Jahja R; Huijbregts SC; de Sonneville LM; van der Meere JJ; Bosch AM; Hollak CE; Rubio-Gozalbo ME; Brouwers MC; Hofstede FC; de Vries MC; Janssen MC; van der Ploeg AT; Langendonk JG; van Spronsen FJ
Mol Genet Metab; 2013; 110 Suppl():S57-61. PubMed ID: 24183792
[TBL] [Abstract][Full Text] [Related]
4. Executive functioning in context: Relevance for treatment and monitoring of phenylketonuria.
Huijbregts SC; Gassió R; Campistol J
Mol Genet Metab; 2013; 110 Suppl():S25-30. PubMed ID: 24206933
[TBL] [Abstract][Full Text] [Related]
5. Are neuropsychological impairments in children with early-treated phenylketonuria (PKU) related to white matter abnormalities or elevated phenylalanine levels?
Anderson PJ; Wood SJ; Francis DE; Coleman L; Anderson V; Boneh A
Dev Neuropsychol; 2007; 32(2):645-68. PubMed ID: 17931123
[TBL] [Abstract][Full Text] [Related]
6. Is BRIEF a useful instrument in day to day care of patients with phenylketonuria?
Liemburg GB; Jahja R; van Spronsen FJ; de Sonneville LM; van der Meere JJ; Bosch AM; Hollak CE; Rubio-Gozalbo ME; Brouwers MC; Hofstede FC; de Vries MC; Janssen MC; van der Ploeg AT; Langendonk JG; Huijbregts SC
Mol Genet Metab; 2015 Mar; 114(3):425-30. PubMed ID: 25541101
[TBL] [Abstract][Full Text] [Related]
7. Screening for cognitive and social-emotional problems in individuals with PKU: tools for use in the metabolic clinic.
Waisbren S; White DA
Mol Genet Metab; 2010; 99 Suppl 1():S96-9. PubMed ID: 20123479
[TBL] [Abstract][Full Text] [Related]
8. Long-term cognitive and psychosocial outcomes in adults with phenylketonuria.
Aitkenhead L; Krishna G; Ellerton C; Moinuddin M; Matcham J; Shiel L; Hossain S; Kiffin M; Foley J; Skeath R; Cleary M; Lachmann R; Murphy E
J Inherit Metab Dis; 2021 Nov; 44(6):1353-1368. PubMed ID: 34145605
[TBL] [Abstract][Full Text] [Related]
9. Reaching out to the lost generation of adults with early-treated phenylketonuria (PKU).
Burton BK; Leviton L
Mol Genet Metab; 2010; 101(2-3):146-8. PubMed ID: 20638310
[TBL] [Abstract][Full Text] [Related]
10. Outcomes beyond phenylalanine: an international perspective.
Feillet F; MacDonald A; Hartung Perron D; Burton B
Mol Genet Metab; 2010; 99 Suppl 1():S79-85. PubMed ID: 20123476
[TBL] [Abstract][Full Text] [Related]
11. The role of intelligence in phenylketonuria: a review of research and management.
Brumm VL; Grant ML
Mol Genet Metab; 2010; 99 Suppl 1():S18-21. PubMed ID: 20123465
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of quality of life in PKU before and after introducing tetrahydrobiopterin (BH4); a prospective multi-center cohort study.
Demirdas S; Maurice-Stam H; Boelen CC; Hofstede FC; Janssen MC; Langendonk JG; Mulder MF; Rubio-Gozalbo ME; van Spronsen FJ; de Vries M; Grootenhuis MA; Bosch AM
Mol Genet Metab; 2013; 110 Suppl():S49-56. PubMed ID: 24100246
[TBL] [Abstract][Full Text] [Related]
13. Psychosocial functioning in children with phenylketonuria: Relationships between quality of life and parenting indicators.
Morawska A; Mitchell AE; Etel E; Kirby G; McGill J; Coman D; Inwood A
Child Care Health Dev; 2020 Jan; 46(1):56-65. PubMed ID: 31782540
[TBL] [Abstract][Full Text] [Related]
14. Depressive symptoms in adolescents with early and continuously treated phenylketonuria: associations with phenylalanine and tyrosine levels.
Sharman R; Sullivan K; Young RM; McGill J
Gene; 2012 Aug; 504(2):288-91. PubMed ID: 22609065
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
Klassen AF; Miller A; Fine S
Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
[TBL] [Abstract][Full Text] [Related]
16. Neuropsychology of early-treated phenylketonuria: specific executive function deficits.
Welsh MC; Pennington BF; Ozonoff S; Rouse B; McCabe ER
Child Dev; 1990 Dec; 61(6):1697-713. PubMed ID: 2083493
[TBL] [Abstract][Full Text] [Related]
17. Executive function in early-treated phenylketonuria: profile and underlying mechanisms.
Christ SE; Huijbregts SC; de Sonneville LM; White DA
Mol Genet Metab; 2010; 99 Suppl 1():S22-32. PubMed ID: 20123466
[TBL] [Abstract][Full Text] [Related]
18. Executive functioning in children and adolescents with phenylketonuria.
VanZutphen K; Packman W; Sporri L; Needham M; Morgan C; Weisiger K; Packman S
Clin Genet; 2007 Jul; 72(1):13-8. PubMed ID: 17594394
[TBL] [Abstract][Full Text] [Related]
19. A comparison of phenylketonuria with attention deficit hyperactivity disorder: do markedly different aetiologies deliver common phenotypes?
Stevenson M; McNaughton N
Brain Res Bull; 2013 Oct; 99():63-83. PubMed ID: 24140048
[TBL] [Abstract][Full Text] [Related]
20. Neurocognitive functioning in adults with phenylketonuria: results of a long term study.
Weglage J; Fromm J; van Teeffelen-Heithoff A; Möller HE; Koletzko B; Marquardt T; Rutsch F; Feldmann R
Mol Genet Metab; 2013; 110 Suppl():S44-8. PubMed ID: 24071437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
